Rituximab is a monoclonal antibody that targets CD20, which is a cell marker found on the cell surface of B-cells. This makes rituximab an effective agent in the treatment of B-cell neoplasms such as non-Hodgkin’s lymphoma and CLL. Rituximab is also useful in the treatment of immune thrombocytopenic purpura and rheumatoid arthritis. However, rituximab has an added side effect of increasing the risk of PML in immunocompromised individuals.
Subscribe for More: bit.ly/2yybxhm
30 июл 2024
